The remarks offset other positive macroeconomic news — including a rebound in retail sales and a sharp decline in jobless claims — to knock the markets lower.
The Nasdaq came out the big loser, down 0.72% to 2,992.16, while the S&P 500 snapped a six-day streak of gains, finishing in the red 0.63% to 1,419.45. The Dow lost 0.61% to end at 80.98.
It wasn’t all bad news, though.
CVS Caremark (NYSE:CVS) headed skyward when the company announced a better-than-expected profit forecast for 2013 and announced a 38% increase in its quarterly dividend. CVS stock finished 2% higher. Shares of Boston Beer Co. (NYSE:SAM) soared by more than 15% after the company raised its full-year forecast, sending the stock to a new 52-week high.
Clearwire (NASDAQ:CLWR) cruised as Sprint (NYSE:S) announced a $2.1 billion offer to buy the rest of the company; shares have cruised nearly 30% in the past three days as buyout news bubbled to the surface.
Several pharma stocks struggled on the day. Rigel Pharmaceuticals (NASDAQ:RIGL) plummeted 35% after the rheumatoid arthritis drug it is licensing to AstraZeneca (NYSE:AZN) didn’t meet an objective in its study. Acura Pharmaceuticals (NASDAQ:ACUR) also lost 11%, while Supernus Pharmaceuticals (NASDAQ:SUPN) fell 8%.
- Oncolytics Biotech (NASDAQ:ONCY): Up 39.6% (86 cents) to $3.03.
- United Continental (NYSE:UAL): Up 7.7% ($1.65) to $23.06.
- JCPenney (NYSE:JCP): Up 6.9% ($1.35) to $20.80.
- Harbinger Group (NYSE:HRG): Down 26.6% ($2.72) to $7.50.
- Allot Communications (NASDAQ:ALLT): Down 11.5% ($2.32) to $17.78.
- Molycorp (NYSE:MCP): Down 6.8% (75 cents) to $10.24.
Alyssa Oursler is an Editorial Assistant at InvestorPlace.com. As of this writing, she did not hold a position in any of the aforementioned securities.